<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00400530</url>
  </required_header>
  <id_info>
    <org_study_id>2006_050</org_study_id>
    <nct_id>NCT00400530</nct_id>
  </id_info>
  <brief_title>Upper GI Handling of Branded vs. Generic Alendronate</brief_title>
  <official_title>A Randomized, Single-Blind Study to Evaluate Upper Gastrointestinal Handling of Branded Versus Generic Alendronate Tablets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      To compare upper GI handling of fosamax and generic, because the main AE profile of
      alendronate is before systemic absorption in the esophagus; differences could be relevant to
      the side effect profile.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gamma camera imaging of tablet dissolution in oesophagus</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gamma camera dissolution of tablets in stomach</measure>
  </secondary_outcome>
  <enrollment>25</enrollment>
  <condition>Osteoporosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK0217, alendronate sodium / Duration of Treatment: 1 Month</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Alendronate-Teva / Duration of Treatment: 1 Month</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Post-menopausal females aged greater 55 years

          -  Prescribed alendronate 70 mg tablets for a therapeutic indication throughout the
             previous 3 months and expected to continue on this treatment for the duration of the
             study

          -  Willing to abstain from alcohol for 24 hours before each dose and until the end of
             each study day

          -  Willing to abstain from smoking for 24 hours before each dose and until the end of
             each study day

        Exclusion Criteria:

          -  History of drug hypersensitivity

          -  Suffers from dysphagia, achalasia, or other conditions or medications affecting upper
             gastrointestinal motility
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <verification_date>November 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2006</study_first_submitted>
  <study_first_submitted_qc>November 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2006</study_first_posted>
  <last_update_submitted>November 16, 2006</last_update_submitted>
  <last_update_submitted_qc>November 16, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2006</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alendronate</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 10, 2014</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>February 14, 2014</submitted>
    <returned>March 28, 2014</returned>
    <submitted>December 8, 2015</submitted>
    <returned>January 11, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

